Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site
29.4.2025 14:00:00 CEST | news aktuell GmbH | Press release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.

Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States.
Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's downtown facility. Biomay's headquarters site is a recently constructed, state-of-the-art biomanufacturing facility.
Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay's business focus from the very beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company's scope of CDMO services comprises process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.
Contact:
Dr. Angela Neubauer, SVP Client Business; E-Mail: request@biomay.com / Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria www.biomay.com
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored17.11.2026 16:00:00 CET | Press release
Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies. Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery. Titia große Broermann: " this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”
PARACELSUS MEDICAL UNIVERSITY: PHARMACY PROGRAM GOES INTERNATIONAL16.11.2026 09:00:00 CET | Press release
Starting in the fall of 2027, the “Pharmacy and Pharmaceutical Sciences” program will be the first English-taught pharmacy program in the German-speaking region to qualify students to work across a range of pharmacy roles and settings.
Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release
Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.
HEIDELBERG sees sequential improvement in business performance in a challenging geopolitical environment12.11.2026 09:07:04 CET | Press release
• Incoming orders high in second quarter of financial year 2026/2027 and around 3 percent higher after six months compared with equivalent period of previous year • Sequential increase in sales and EBITDA margin during financial year • Focus on strategic priorities – integration of manroland sheetfed proceeding according to plan • Geopolitical crises and advance outlay hit profitability • Forecast for financial year 2026/2027 – stable sales and adjusted EBITDA margin of between 5.6 and 6.6 percent
Polarise plans to add roughly 150 megawatts of new AI capacity in Germany by the end of 2028 - Named “Hidden Champion” by the German AI Association12.11.2026 08:49:30 CET | Press release
Upcoming AI Factories will be established in Bavaria, Hesse, and North Rhine-Westphalia - the award recognizes the development of sovereign AI infrastructure
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom